转移性去势抵抗前列腺癌患者接受达沙替尼和多西他赛联合治疗后长期使用达沙替尼的效果
转移性去势抵抗前列腺癌患者接受达沙替尼和多西他赛联合治疗后长期使用达沙替尼的效果Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of&nbs
转移性去势抵抗前列腺癌患者接受达沙替尼和多西他赛联合治疗后长期使用达沙替尼的效果
Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
Abstract: Dasatinib is a potent oral tyrosine kinase inhibitor which targets several kinases, including the SRC family kinases. SRC family kinases have been implicated in androgen therapy resistance that often develops in metastatic castration-resistant prostate cancer (mCRPC), which drives the need for non-androgen targeting therapies. This article describes the preclinical rationale for the use of combination dasatinib and docetaxel therapy in mCRPC, and highlights the results of a phase I–II trial in which 46 patients with mCRPC, treated with a regimen of dasatinib and docetaxel, demonstrated improvements in bone scans, high rates of soft tissue responses, and modulation of markers of bone turnover. This brief report discusses in detail follow-up data on two patients who remain alive after >2.5 years on dasatinib single-agent therapy after discontinuing docetaxel treatment.
Keywords: case study, dasatinib, docetaxel, prostate cancer, targeted therapy
相关文章
评论
我要跟帖
